Alzheimer’s Disease

Phase II/III GAIN trial results: atuzaginstat for disease modification in Alzheimer’s disease

Caspase-6-cleaved tau in Alzheimer’s disease

Changes in Rhes distribution associated with tau accumulation and neuronal vulnerability

Investigating differences in selective neuronal vulnerability in typical and atypical AD

Mass spectrometry-based proteomics identifies progressive changes in tau PTMs over time

Phase IIb ELAD trial of liraglutide in mild-moderate Alzheimer’s disease

Beyond amyloid & tau: neuroinflammation, rhes & proteomics

Advances in methodology for structural biology of neurodegeneration

Detecting microglial activation in Alzheimer’s disease

The impact of sex on Alzheimer’s disease presentation in adults with Down syndrome

The potential of lecanemab for the treatment of early Alzheimer’s disease

Age at onset of Alzheimer’s disease is consistent in adults with Down syndrome

AD pathology isn’t always associated with memory loss

The potential of plasma biomarkers in dementia

Donanemab: breakthrough therapy designation based on TRAILBLAZER data

What underlies the manifestation differences seen in atypical AD?